Get the Stockscreener App
1.16
0.00%
0.00
Pre-market:
1.13
-0.03
-2.59%
Bioatla Inc stock is traded at $1.16, with a volume of 1.71M.
It is up +0.00% in the last 24 hours and up +88.93% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$1.16
Open:
$1.17
24h Volume:
1.71M
Relative Volume:
1.32
Market Cap:
$68.12M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.4479
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
+75.84%
1M Performance:
+88.93%
6M Performance:
+196.22%
1Y Performance:
-21.62%
1-Day Range:
$1.10
$1.31
1-Week Range:
$0.636
$1.43
52-Week Range:
$0.2601
$1.90
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
1.16 | 68.20M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
BioAtla Secures $7.5 Million Pre-Paid Advance - TipRanks
BioAtla’s New Funding: A Double-Edged Sword for Shareholders - Ad-hoc-news.de
BioAtla Agrees to $22.5 Million in Financing Agreements - MarketScreener
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - Investing News Network
BioAtla, Inc. Secures $7.5 Million Financing to Support Operations During Strategic Partnership Negotiations - Quiver Quantitative
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewswire Inc.
Is BioAtla Inc (BCAB) Good For Your Portfolio? - fostersleader.com
Regression analysis insights on BioAtla Inc. performanceWeekly Trend Summary & AI Enhanced Market Trend Forecasts - newser.com
What catalysts could drive BioAtla Inc. stock higherProfit Target & Fast Gain Swing Trade Alerts - newser.com
Measuring BioAtla Inc.’s beta against major indicesTrade Analysis Report & Community Consensus Trade Alerts - newser.com
BioAtla Inc. stock outlook for YEAR2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - newser.com
Bioatla Shares Surge on Strong Clinical and Financial Results - Ad-hoc-news.de
Sentiment analysis tools applied to BioAtla Inc.Take Profit & Verified Momentum Watchlists - newser.com
What moving averages say about BioAtla Inc.Portfolio Return Summary & Accurate Entry/Exit Alerts - newser.com
BioAtla Inc (BCAB) can make a big difference with a little luck - Setenews
Analyzing BioAtla Inc. with multi timeframe chartsMarket Sentiment Report & High Accuracy Swing Entry Alerts - newser.com
Analyzing BioAtla Inc. with risk reward ratio chartsTrade Performance Summary & Weekly Watchlist of Top Performers - newser.com
What to do if you’re stuck in BioAtla Inc.Sell Signal & Reliable Price Action Trade Plans - newser.com
Chart overlay techniques for tracking BioAtla Inc.July 2025 Sentiment & Technical Confirmation Alerts - newser.com
Is BioAtla Inc. a candidate for recovery playGap Down & AI Powered Trade Plan Recommendations - newser.com
BioAtla, Inc. (NASDAQ:BCAB) Q3 2025 Earnings Call Transcript - Insider Monkey
BioAtla Tightens Belt But Analysts Remain Upbeat - Finimize
BioAtla Reports Q3 2025 Financial Results and Progress - TipRanks
BioAtla Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Bioatla Q3 2025 shows stable EPS, stock dips - Investing.com India
BioAtla (BCAB) Q3 2025 Earnings Call Transcript - AOL.com
BioAtla, Inc. Q3 Earnings Call Highlights Progress and Challenges - TipRanks
Transcript : BioAtla, Inc., Q3 2025 Earnings Call, Nov 13, 2025 - MarketScreener
Earnings call transcript: Bioatla Q3 2025 shows stable EPS, stock dips By Investing.com - Investing.com Canada
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... By GuruFocus - Investing.com Canada
BioAtla Q3 net loss widens to $15.8 mln - MarketScreener
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Investing News Network
BioAtla, Inc. (BCAB) Q3 FY2025 earnings call transcript - Yahoo Finance
Press Release: BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - 富途牛牛
What analysts say about BioAtla Inc stockMean Reversion Trades & Explosive Profit Trading - earlytimes.in
What's Next: BioAtla's Earnings Preview - Benzinga
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):